肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Oncology：联合mRECIST和AFP比率有助评估肝细胞癌患者预后

2012-08-16 君亭 医学论坛网

mRECISTAFP比率肝细胞癌
关注

　　《肿瘤学》（Oncology）杂志近期发表的一项研究表明，联合应用改良的实体瘤疗效评价标准（mRECIST）和α甲胎蛋白（AFP）比率有助于评估接受索拉非尼治疗的晚期肝细胞癌（HCC）患者预后。 　　该研究是一项回顾性研究，共纳入了66例接受索拉非尼治疗的晚期HCC患者。治疗反应情况通过RECIST、mRECIST以及AFP和脱-γ-羧基凝血酶原（DCP）的变化来评估。 　　结果显示，患者

　　《肿瘤学》（Oncology）杂志近期发表的一项研究表明，联合应用改良的实体瘤疗效评价标准（mRECIST）和α甲胎蛋白（AFP）比率有助于评估接受索拉非尼治疗的晚期肝细胞癌（HCC）患者预后。

　　该研究是一项回顾性研究，共纳入了66例接受索拉非尼治疗的晚期HCC患者。治疗反应情况通过RECIST、mRECIST以及AFP和脱-γ-羧基凝血酶原（DCP）的变化来评估。

　　结果显示，患者中位生存期为8.6个月。中位至放射学进展时间为3.3个月。RECIST和mRECIST评出的缓解 [完全缓解（CR）+部分缓解（PR）] 率分别为3.0%和9.0%，而疾病控制[CR+PR+疾病稳定（SD）]率均为50%。

　　多变量分析显示，mRECIST缓解（CR+PR+SD，P=0.001）、治疗8周时AFP比率（≤1，P=0.046）和治疗前Child-Pugh A级（P=0.012）是患者生存的显著和独立的决定因素。DCP比率无助于评估患者总生存。

　　联合应用治疗8周时AFP比率、mRECIST和治疗前Child-Pugh评级可对接受索拉非尼治疗的患者预后进行分层。

　　相关链接：Tomokazu Kawaoka, Hiroshi Aikata, Eisuke Murakami, Takashi Nakahara, Noriaki Naeshiro, Mio Tanaka, Yoji Honda, Daisuke Miyaki, Yuko Nagaoki, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Shoichi Takahashi, Kazuaki Chayama.Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib.Oncology 2012;83:192-200 (DOI: 10.1159/000341347


 



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-12-14 xuyu

    #mRECIST#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2013-04-16 minlingfeng

    #Oncol#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-08-16 xjy02

    #肝细胞#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-09-20 12498ebem19暂无昵称

    #CIS#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-08-29 mxj1971619

    #AFP#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-10-09 circumcision

    #Oncology#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2013-04-03 cqlidoudou

    #RECIST#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2013-06-09 qingting

    #细胞癌#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-12-13 bnurmamat

    #患者预后#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1943494, encodeId=99681943494aa, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Fri Dec 14 11:33:00 CST 2012, time=2012-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864378, encodeId=038518643e853, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Apr 16 20:33:00 CST 2013, time=2013-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863195, encodeId=86541863195e2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 16 21:33:00 CST 2012, time=2012-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993588, encodeId=6f44199358899, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Sep 20 16:33:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633245, encodeId=372f163324588, content=<a href='/topic/show?id=08a220e6ce' target=_blank style='color:#2F92EE;'>#AFP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2076, encryptionId=08a220e6ce, topicName=AFP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b922043063, createdName=mxj1971619, createdTime=Wed Aug 29 14:33:00 CST 2012, time=2012-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674325, encodeId=8ca516e4325ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Tue Oct 09 11:33:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079710, encodeId=c17420e97104c, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Wed Apr 03 12:33:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978333, encodeId=957b19e83336c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Jun 09 13:33:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691796, encodeId=06dc1691e96db, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Thu Dec 13 15:33:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048228, encodeId=fca62048228d3, content=<a href='/topic/show?id=12e620e8e7' target=_blank style='color:#2F92EE;'>#AFP比率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2078, encryptionId=12e620e8e7, topicName=AFP比率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Fri Nov 09 10:33:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-11-09 songbq

    #AFP比率#

    0

以上为热门评论，梅斯医学App还有更多内容